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HIGHLIGHTS  
i. What is already known about the topic? 
i. Influenza causes substantial burden to patients. Most patients who are infected with 
influenza do not die or experience serious complications but nearly all experience a 
bothersome array of symptoms. 
ii. There is no standardized measure of influenza symptoms developed according to current 
best practices and scientific methodology. 
ii. What does the paper add to existing knowledge? 
i. A standardized measure of influenza symptoms could be used in clinical trials evaluating 
medical interventions for treatment or prevention, epidemiology and natural history 
studies, and transmission and challenge studies. A standardized symptom measure 
could also be combined with other baseline variables. 
ii. Prior work has evaluated the content validity and understandability of the FLU-PRO 
symptom scale. The evidence from this study on the measurement properties of the FLU-
PRO shows that it is reliable, has known-groups and construct validity, and demonstrates 
responsiveness to change over time as symptoms change in outpatients and hospitalized 
patients. 
iii. (optional) What insights does the paper provide for informing health care-related decision 
making? 
i. FLU-PRO is ready for use in clinical trial and in epidemiology studies. FLU-PRO provides 
a valid, reliable and responsive standardized measure of influenza symptoms that can be 
used to evaluate patient-reported outcomes either alone or in combination with other 
outcomes to accurately assess the burden of illness in epidemiological studies and 
treatment effects in clinical trials of medical interventions. 
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ABSTRACT (MAX: 250 WORDS) – CURRENT: 249 
Objectives: Assess the reliability, validity, and responsiveness of FLU-PRO© scores for quantifying the 
presence and severity of influenza symptoms.  
Methods: Observational prospective cohort study of adults (≥18 years) with influenza-like illness in US, 
UK, Mexico, and South America. Participants completed the 37-item draft FLU-PRO daily for up to 14-
days. Item-level and factor analyses were used to remove items and determine factor structure. Reliability 
of the final tool was estimated using Cronbach’s alpha and intraclass correlation coefficients (ICC; 2-day 
reliability). Convergent and known-groups validity and responsiveness were assessed using global 
assessments of influenza severity and return to usual health. 
Results:  Of 536 enrolled, N=221 influenza-positive subjects comprised the analytical sample. Mean 
age=40.7, 60.2% female, 59.7% white. The final 32-item measure has 6-factors/domains (Nose Throat, 
Eyes, Chest/Respiratory, Gastrointestinal, Body/Systemic) with a higher-order factor representing 
symptom severity overall (comparative fit index [CFI]=0.92; root mean square error of approximation 
[RMSEA]=0.06). Cronbach’s alpha was high (Total=0.92; domain range=0.71-0.87; test-retest reliability 
(ICC, Day 1–2) was 0.83 for total scores and 0.57 to 0.79 for domains. Day 1 FLU-PRO domain and total 
scores were moderately-to-highly correlated (≥0.30) with Patient Global Rating of Flu Severity (except 
Nose and Throat). Consistent with known-groups validity, scores differentiated severity groups based on 
global rating (Total; F=57.2, p<0.001; domains: F=8.9-67.5, p<0.001). Subjects reporting return to usual 
health showed significantly greater (p<0.05) FLU-PRO score improvement Day 7 than those who did not, 
suggesting score responsiveness. 
Conclusions: Results suggest FLU-PRO scores are reliable, valid, and responsive to change in influenza 
positive adults.   
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INTRODUCTION (Total Word Limit: 4000; Current: 4,003) 
Influenza (flu) is an acute illness caused by influenza viruses [1]. Symptoms can range from mild to 
severe, and include fever/chills, cough, sore throat, runny or stuffy nose, fatigue, muscle/body aches, with 
gastrointestinal symptoms (diarrhea and vomiting) occurring less frequently [2].  
In the United States (US), approximately 5%–20% of the population is infected with influenza yearly, with 
approximately 200,000 hospitalizations and 36,000 deaths [1-3]. Worldwide, influenza causes 
approximately 3–5 million severe cases and 250,000–500,000 deaths annually [4]. While most patients 
recover, during their illness these patients experience symptoms that impair their daily functioning. 
Currently, no standardized, validated patient-reported outcome (PRO) measure for influenza and 
influenza-like symptoms has been developed using good research practices for scale development 
methods [6-8], such as those recommended by the US Food and Drug Administration (FDA) [5]. A 
standardized patient-reported influenza symptom scale would allow for consistent, accurate assessments 
of the characteristic symptoms associated with various viral strains and their corresponding severity in 
population-level epidemiologic studies, natural history studies on the course of influenza, studies 
comparing influenza subtypes within and across years, and clinical trials. For treatment trials, a precise, 
standardized patient-reported influenza symptom scale will allow clinical trials to detect differences 
between interventions with greater accuracy and facilitate cross-product evaluations and meta-analysis. 
The InFLUenza Patient-Reported Outcome (FLU-PRO©) measure was designed to assess the 
occurrence and severity of influenza symptoms; used as a daily diary, the FLU-PRO can track changes 
over time, during the course of an influenza episode. Two-stage qualitative instrument development 
methodology was used to create this new measure [9]. Stage I involved concept elicitation interviews in 
the US and Mexico to gather information regarding patient experience of influenza symptoms (i.e., type, 
magnitude, expression, pattern of onset, and recovery). Results informed the development of the draft 
FLU-PRO, including content, structure (item phrasing, length, response options, recall, instructions), and 
conceptual framework. Stage II consisted of cognitive interviews to assess completeness, 
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comprehension, interpretability, and ease of use of the draft measure from the respondent’s perspective, 
refining the instrument to assure content validity.  
This study assessed the performance properties of the FLU-PRO in adults ≥18 years of age with acute 
laboratory-confirmed influenza. Specifically, the objectives of this study were to: 1) evaluate individual 
item performance and measurement/domain structure; 2) reduce the number of items as empirically and 
conceptually appropriate; 3) develop a scoring algorithm; and 4) assess the reliability, construct and 
known-groups validity, and responsiveness of FLU-PRO total and domain scores. 
METHODS 
Study Design and Sample 
This was a prospective, observational study of English and Spanish-speaking hospitalized and non-
hospitalized adults ≥18 years of age with acute influenza. Patients seeking care for influenza symptoms at 
participating clinics in the US (16 sites), Argentina (two sites), United Kingdom (one site), and Mexico 
(three sites) were recruited during clinic visits. Influenza status was assessed through a positive PCR, 
rapid antigen test, and/or viral culture by nasal or nasopharyngeal swab.  
Procedures 
Clinical research coordinators recruited all participants with influenza-like symptoms and tested for 
laboratory confirmed influenza diagnosis to determine the primary analytical sample. The FLU-PRO study 
sample was recruited as part of a larger outpatient study. Consented patients completed clinic-based 
baseline assessments of sociodemographic and clinical characteristics. Patients completed a daily diary 
for 14 days following enrollment that included the 37-item draft FLU-PRO symptom diary and nine 
additional questions for validation purposes. At the Mexico site, the diary was completed via personal 
telephone interview with data entered directly into a web-based portal.  Patients in 16 US sites, one UK 
site, and two Argentina sites completed the survey either via interviewer-administration or a via web-
based system using the subject’s personal web-enabled device,  
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The study was conducted with informed consent, under institutional review board approval, and in 
accordance with the Declaration of Helsinki. 
Instruments: Patient-reported Outcomes (PROs) 
InFLUenza Patient-Reported Outcome (FLU-PRO©) 
The draft FLU-PRO Questionnaire instructed respondents to rate the severity of 37 influenza symptoms 
over the past 24 hours. Symptoms included those related to the nose, throat, eye, chest, head, stomach, 
fatigue, and body aches/pains based on concepts elicited from patients in Stage I. Six items measured 
the same symptom using different wording to select the best performing item for the final instrument. For 
32 of 37 items, respondents rated the severity of each symptom on a 5-point Likert-type scale from 0 
(“Not at all), 1 (“A little bit”), 2 (“Somewhat”), 3 (“Quite a bit”), to 4 (“Very much”). For the five remaining 
items, symptom severity is expressed in terms of frequency of occurrence: vomiting or diarrhea (0 times, 
1 time, 2 times, 3 times, or 4 or more times), and sneezing, coughing, and coughed up mucus or phlegm 
on a scale from 0 (“Never”) to 4 (“Always”), with higher scores indicating more severe symptoms.  
The questionnaire was developed for self-report or interviewer-administration, with slight differences in 
the instructions applicable for each administration. 
Patient Global Rating of Flu Severity 
The Patient Global Rating of Flu Severity is a single item to assess participants’ overall influenza 
symptom severity. Participants were asked to rate severity on the following scale: 0 (“No flu symptoms 
today”), 1 (“Mild”), 2 (“Moderate”), 3 (“Severe”), and 4 (“Very severe”). 
Patient Global Assessment of Interference with Daily Activities 
The Patient Global Assessment of Interference in Daily Activities is a single item to assess interference in 
daily activities due to influenza symptoms during that day. Participants rated interference on the following 
scale: 1 (“Not at all”), 2 (“A little bit”), 3 (“Somewhat”), 4 (“Quite a bit”), and 5 (“Very much”). 
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Patient Global Assessment of Physical Health 
The Patient Global Assessment of Health is a single item to assess general physical health during that 
day. Participants rated their physical health on the following scale: 1 (“Poor”), 2 (“Fair”), 3 (“Good”), 4 
(“Very good), and 5 (“Excellent”). 
Return to “Usual” Health and Activities 
Patients were asked to respond (yes/no) to the following questions: “Have you returned to your usual 
activities today?” and “Have you returned to your usual health today?” 
Statistical Analyses 
Statistical tests were performed in accordance with classical test theory [10]. Analyses were conducted in 
two phases: 
Phase I: Item evaluation and item reduction, including descriptive item statistics, floor and ceiling 
effects, item-to-item correlations, confirmatory factor analysis (CFA), and exploratory factor 
analysis (EFA) [11]. Analyses were performed on data from the entire influenza positive cohort.  
Results from these analyses were used to inform item deletion or retention and determine the 
scoring algorithm for the final FLU-PRO.  
Phase II: Evaluation of psychometric properties of the FLU-PRO total and domain scores, 
including reliability, construct and known-groups validity, and responsiveness. These analyses 
were performed on the entire influenza positive cohort and stratified by hospitalization status. 
Phase I: Item Evaluation, Item Reduction, and Domain Structure of the FLU-PRO 
Item Analysis 
Day 1 data were used to examine distributional characteristics of the 37 items comprising the draft FLU-
PRO, including mean, median, range, mode, percentages of minimum and maximum responses for floor 
and ceiling effects, percentage missing, and the frequency and percent of each response category. An 
item was flagged for potential problems if it showed a floor (minimum response >25%) or ceiling effect 
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(maximum response >25%). Spearman correlations were used to calculate inter-item correlations among 
all 37 FLU-PRO items at day 1. 
Confirmatory Factor Analysis (CFA) 
CFA was used to assess fit of FLU-PRO according to a hypothesized 3-domain structure (Supplement 
Figure S1), including Upper Respiratory (items measuring nose, throat, and eye symptoms), Lower 
Respiratory (items measuring chest symptoms), and Systemic (items measuring head, gastrointestinal, 
sleep, and body/systemic symptoms) domains on day 1.  
The hypothesized factor model was tested using a weighted least squares mean and variance adjusted 
(WLSMV) estimator. The CFA model fit was assessed with the comparative fit index (CFI), root mean 
square error of approximation (RMSEA), and weighted root mean square residual (WRMR). CFI greater 
than 0.90 was considered an acceptable fit, RMSEA <0.07, and WRMR close to 1 [12, 13]. Items with 
standardized coefficient <0.30 were reviewed for possible deletion. CFA was conducted using Mplus 
software [14]. 
Exploratory Factor Analysis (EFA) 
EFA was conducted in the case of misfit of the hypothesized model according to the CFA. For the EFA, 
there was no pre-specified number of factors. Values for CFI, standardized root mean square residual 
(SRMR), and RMSEA were examined to assess model goodness-of-fit. Acceptable model-fit was 
indicated when values of SRMR <0.08 [15] and RMSEA <0.07 [12, 13]. Approximation of simple structure 
with factor loadings ≥0.4 was the criterion for accepting a factor solution; oblique rotation was used. EFA 
was conducted using Mplus software [14]. 
Phase II: Evaluation of Psychometric Properties 
Reliability (Internal and Test-retest) 
Cronbach’s formula for coefficient alpha was used to estimate internal consistency reliability of the FLU-
PRO Total and domain scores as appropriate at day 1. Coefficients of 0.7 to 0.9 were pre-specified as 
“good” internal consistency, 0.4 to <0.7 as moderate, and <0.4 as low or poor [10, 16].  
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Data from patients whose influenza severity state was unchanged over time were used to estimate the 
test-retest reliability of FLU-PRO Total and domain scores. Stable subjects were defined as those with “no 
change” on the Patient Global Rating of Change in Flu Severity using two consecutive days from Week 1 
(day 1 to day 7). If a subject was missing FLU-PRO scores for one of the days in the planned 
comparison, data for this subject was excluded from that pair of days’ evaluation. Intraclass correlation 
coefficients (ICC from a fixed effects model) along with paired t-tests, and effect size (ES) were performed 
to evaluate score stability. ICCs were expected to be at least moderate, exceeding 0.60. Mean 
differences between the two observations were expected to be minimal with small ES (<0.20);  
Construct Validity 
Construct validity is the degree to which a measure is related to other measures or constructs in a 
manner that is consistent with theory. The relationship between the FLU-PRO Total and domain scores 
and three global ratings were assessed using Spearman correlations to test for construct validity at day 1 
and day 3. Correlations between the FLU-PRO were anticipated to be the strongest with the Patient 
Global Rating of Flu Severity, followed by the Patient Global Rating of Physical Health, and the Patient 
Global Assessment of Interference with Daily Activities, which were hypothesized to be the more distal 
constructs. However, it was hypothesized that correlations between the FLU-PRO and all three global 
ratings would be moderate to high (>0.30) to support construct validity [17].  
Known-groups Validity 
Known-groups validity involves evaluating an instrument in relation to score differences between two or 
more groups known to differ on the underlying construct. [18].  In this case, analysis of variance (ANOVA) 
was used to compare FLU-PRO Total and domain scores across three Patient Global Rating of Flu 
Severity categories at day 1: “None” or “Mild”; “Moderate”; and “Severe” or “Very severe”. Mean (SD), F-
scores, and p-values were reported to determine the magnitude of the differences. Pairwise comparisons 
between means were performed using Scheffe’s test adjusting for multiple comparisons. 
Responsiveness 
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Ability to detect change refers to the extent to which the PRO instrument can detect change in patients 
whose clinical status has changed [19]. Analysis of covariance (ANCOVA) was used to compare changes 
in FLU-PRO scores at day 7 in the responders (those returning to usual health or activity) and non-
responders (those not returning to usual health or activity) adjusting for day 1 scores. Responders were 
defined using the two different anchors in two separate analyses. It was expected that responders would 
have significantly larger (p <0.05) change scores than non-responders.  
RESULTS 
Sample 
A total of 536 English and Spanish-speaking hospitalized and non-hospitalized patients were enrolled, 
with 441 included in the analytic dataset (had day 1 diary assessment and >1 post-day 1 diary entry). Of 
these 441, 221 were influenza positive and included in the psychometric analyses (Supplement Figure 
S2). Table 1 presents baseline demographic and clinical characteristics for influenza positive patients. 
Phase I: Item Evaluation, Item Reduction, and Domain Structure of the FLU-PRO 
Item Analysis 
The distributional characteristics of FLU-PRO items were examined at day 1. The full range of response 
options was utilized for all 37 items; 25 items were flagged for further evaluation due to floor effects. 
(Supplement Table S1). 
Spearman inter-item correlation coefficients among FLU-PRO items at day 1 correlated as expected; no 
correlations were above 0.80 to indicate a high level of redundancy between items (data not shown). 
Confirmatory Factor Analysis 
A CFA was conducted to assess the fit of the original hypothesized 3-factor model, with factors for Upper 
Respiratory, Lower Respiratory, and Systemic symptoms (Supplement Table S2). This model 
demonstrated unacceptable global fit (CFA = 0.836; RMSEA = 0.089; WRMR = 1.722) and one item 
demonstrated misfit (Q23: Sleeping more than usual).  
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Exploratory Factor Analysis and Item Reduction 
Given the CFA result, EFA was conducted to allow the data to drive the factor structure. Models with 4–
15 factors showed acceptable fit indices. However, the 7-factor solution best approximated the 
hypothesized conceptual framework, was clinically interpretable, and achieved the best fit (Supplement 
Table S3). The 7-factor solution was composed of Nose, Throat, Eyes, Chest, Head/Body, 
Gastrointestinal, and Sleep domains.  
Individual items were further examined relative to their item-level performance, this factor structure, and 
qualitative data gathered during Phase I. The sleep domain was removed, with the remaining sleep item 
incorporated into the Body/Systemic domain. The items Q24: Difficulty staying asleep and Q25: Difficulty 
falling asleep were removed due to poor fit in modeling as these items represent opposite problems with 
sleep. 
Revised Conceptual Framework and Scoring 
The final conceptual framework for the FLU-PRO is shown in Figure 1. The final scaling model is 
composed of a 6-factor structure (Nose [4 items], Throat [3 items], Eyes [3 items], Chest/Respiratory [7 
items], Gastrointestinal [4 items], and Body/Systemic [11 items]), with a higher-order factor representing 
influenza symptom severity and has the following fit indices: CFI = 0.92; RMSEA = 0.06, and WRMR = 
1.23.  
A mean-based scoring algorithm was selected, where domain and total scores can be calculated by 
computing the mean within each domain or across all 32 items, respectively.  Scores range from 0 to 4 
with higher scores indicating more severe symptoms. 
Phase II: Evaluation of Psychometric Properties 
Results for the influenza positive patient sample overall are reported below; results of stratified analyses 
are provided in the online supplement. 
Descriptive Statistics of FLU-PRO Total and Domain Scores 
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The distributional characteristics of the FLU-PRO domain and Total scores were examined at day 1 
(Table 2). Mean domain scores ranged from 0.7 (SD=0.8) for the Gastrointestinal domain to 1.9 (SD=0.9) 
for the Chest/Respiratory domain. Floor effects were observed for the Eyes (30%) and Gastrointestinal 
(35%) domains, but no ceiling effects were evident. Figure 2 shows the decline in mean FLU-PRO Total 
and domain scores day 1 to day 14. 
Reliability (Internal and Test-retest) 
Cronbach’s alpha was high for all domains (Nose=0.81, Throat=0.81, Eyes=0.81, 
Chest/Respiratory=0.80, Gastrointestinal=0.71; Body/Systemic=0.87) and the Total score (0.92). Only the 
removal of two items would have increased domain score alpha (Q6: Difficulty swallowing; Q34: How 
many times did you have diarrhea?); however, this change was insufficient to warrant removal from the 
final instrument.  
Data from patients whose global rating of influenza severity was unchanged over the analytical time 
period were used to evaluate reliability. From day 1 to day 2 (n=44), score reliability for Eyes (ICC=0.62), 
Chest/Respiratory (ICC=0.76), Gastrointestinal (ICC=0.62), and Body/Systemic (ICC=0.65) domains were 
considered acceptable according to the ES and ICC estimates, while the Nose (ICC=0.79) and Total 
score (ICC=0.83) were acceptable according to the ICC estimate (Throat values did not meet thresholds; 
ICC=0.57). At all other two-day assessment points, FLU-PRO ES and ICCs estimates were acceptable 
(except Body/Systemic at day 2 to 3 and 6 to 7) (Supplement Table S4). 
Construct Validity 
As hypothesized, at day 1 the strongest association was evidenced between the FLU-PRO Total score 
and the Patient Global Rating of Flu Severity (r=0.59, p<0.0001), followed by the Patient Global 
Assessment of Interference in Daily Activities (r=0.43, p<0.0001) and Patient Global Rating of Physical 
Health (r=-0.29, p<0.0001) (Supplement Table S5). Domain scores displayed moderate to large 
associations with the Patient Global Rating of Flu Severity (r=0.34 to 0.61) with the exception Nose 
(r=0.27) and Throat (r=0.28), with all coefficients statistically significant (p<0.0001). A moderate to large 
correlation was demonstrated between the Body/Systemic domain and the more distal Patient Global 
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Assessment of Interference with Daily Activities (r=0.50, p<0.0001); correlations between this global 
rating and the other FLU-PRO domains were smaller (r=0.11 (n.s.) to 0.29 (p<0.0001)). Similarly, weaker 
associations were demonstrated between the FLU-PRO domains and the Patient Global Rating of 
Physical Health with coefficients ranging from 0.06 (n.s.) to 0.28 (p<0.0001).  
Known-groups Validity 
Significant differences in FLU-PRO scores were observed across the patient global symptom severity 
rating groups (F=57.2, p<0.001).  Mean [SD] scores were lowest in the No/Mild Symptoms group (0.98 
[0.47]), followed by the Moderate (1.38 [0.57]) and Severe/Very Severe groups (2.01 [0.63]) with all 
pairwise comparisons statistically significant (p<0.001). For the FLU-PRO domain scores, the mean 
values for the No/Mild group were the lowest (mean range = 0.29 to 1.37), followed by the Moderate 
group (mean range = 0.48 to 1.75) and the Severe/Very Severe group (mean range = 1.06 to 2.48). 
Pairwise comparisons for each domain score showed a similar pattern to the Total score with the 
exception of the No/Mild symptoms versus Moderate for the Nose, Throat, Eyes, and Gastrointestinal 
domains, which were in the correct direction but nonsignificant (p>0.05) (Table 3). 
Responsiveness 
Mean total and domain change scores were significantly greater for patients reporting a return to usual 
health (responders) by day 7, compared to those who did not, with the exception of the Gastrointestinal 
domain (Table 4).  Mean change scores were also significantly greater for patients reporting return to 
usual activities (responders) by day 7 compared to those who did not, with the exception of the Eyes 
domain (Table 4).   
DISCUSSION 
The purpose of this study was to finalize content, structure, and scoring of the FLU-PRO and assess the 
performance properties of this new instrument in adults with laboratory-confirmed influenza [5].  A reliable 
and accurate measurement tool to quantify symptoms of influenza in hospitalized and non-hospitalized 
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patients will facilitate the conduct of population-level epidemiologic studies, natural history studies, and 
clinical trials. 
The 37-item draft FLU-PRO was developed based on patient descriptions of influenza and included 
content-redundant items for evaluation and elimination during quantitative analysis [9].  Five redundant 
and lower-performing items were removed to yield a 32-item questionnaire. Through a series of factor 
analyses, 6-domains were identified, with content consistent with body systems commonly affected by 
influenza.  A mean-based scoring algorithm is used to represent the average symptom severity across 
symptoms within each domain/body system, with a total score representing symptom severity overall. 
Given the FLU-PRO’s relatively high internal consistency levels, this allows calculation of a domain score 
in the presence of up to 50% item-level missing data. To assure representation of all body systems in the 
overall score, total scores are computed across all items comprising the measure only if there is also 
sufficient data to compute each domain score.   
Results suggest FLU-PRO scores are reliable, demonstrate construct and known-groups validity, and are 
responsive to improvements in health as patients recover from influenza.  Floor effects were seen for 
some items due to low prevalence for those symptoms with the circulating strain of influenza. Internal 
consistency and 2-day test-retest reliability were strong for the total and domain scores.  Consistent with 
a priori hypotheses, FLU-PRO scores were significantly related to patient global ratings of influenza 
severity, interference with activities, and physical health.  The data supported known-groups validity as 
FLU-PRO scores were lowest in patients rating their symptoms as None/Mild, higher in the Moderate, and 
highest with Severe/Very Severe. Finally, the FLU-PRO demonstrated responsiveness to change from 
day 1 to 7, with responders defined by reports of return to usual health and activities. 
In FLU-PRO Stage I, concept elicitation interviews with adults and children with influenza were used to 
develop a comprehensive list of symptoms. Stage II confirmed the ease of understanding item phrasing 
and ensured content coverage [9]. The 37-item draft instrument could be completed in five minutes or 
less, showing low respondent burden. The final 32-item FLU-PRO is more comprehensive than existing 
influenza symptom measures which are limited to the most prevalent symptoms of influenza, such as the 
11-item Influenza Symptom Severity Scale (ISS; [20]) and the 10-item FluiiQTM [21], with the latter 
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assessing two domains, systemic and respiratory. Quantitative analyses in the present study indicated 
that the performance of the FLU-PRO was optimized after the removal of only five items, thus the final 
FLU-PRO remains an inclusive instrument with a broad range of bodily symptoms experienced by 
patients, enabling greater precision and accuracy for evaluating symptom severity and recovery. 
Although FluiiQ [21] was developed in a manner generally consistent with the 2009 FDA PRO Guidance 
[5] and has been used in clinical trials [22], it has several limitations that are addressed in the FLU-PRO. 
Specifically, FluiiQ has shown low reliability in the respiratory domain (3 items) [21]. This single domain 
consists of items that measure cough, sore throat, and nasal congestion symptoms. However, in the 
domain structure analysis of the FLU-PRO using CFA and EFA, best fit with high reliability was achieved 
by utilizing three separate domains to assess symptoms in nose, throat, and chest/respiratory systems. 
Further, each of these three constructs are measured by more than one symptom, in order to more 
precisely measure changes in symptoms in these body systems. The FLU-PRO also includes an entire 4-
item domain to assess a variety of gastrointestinal symptoms, which is absent from the FluiiQ and noted 
with some strains of influenza. Finally, in terms of the patient populations, the FLU-PRO was developed 
and evaluated in patients in the US and Mexico—where content coverage and performance was found to 
be similar in both countries—whereas the FluiiQ was only developed in the US. Further, both hospitalized 
and non-hospitalized patients were included in the FLU-PRO development samples. To date, no other 
measure of influenza symptoms has been evaluated in hospitalized patients.  
The current study had several limitations worth noting. First, although hospitalized patients were included 
in the validation patient population, specific details about the event (e.g., duration of influenza prior to 
hospitalization, acuity level during hospitalization, concurrent complicating conditions) are unknown. 
Results suggest the FLU-PRO performs consistently in hospitalized and clinic-based samples, however 
additional study in acute care settings is warranted. Second, missing data increased over time, 
particularly after the day 2 observation (i.e., approximately 25.2% did not complete the FLU-PRO on days 
1, 2, and 3). Three- and 7-day compliance was higher in patients outside the US compared to US sites. 
Specifically, 52.7% of patients in the US completed the diary on all days from day 1 through day 3 
compared to 88.7% of patients outside the US. By day 7, this value dropped to 28.0% and 81.7% for US 
16 
and ex-US sites, respectively. This may be due, in part, to the interviewer administered methods used in 
several ex-US sites.  An examination of patterns of missing data indicated patients discontinued the daily 
survey as their symptoms resolved; 90.0% of patients completed the diary to symptom resolution 
indicating high rates of compliance during the most relevant days of data collection..  
The content validity of the FLU-PRO has been established in children and adolescents through qualitative 
research. Next steps are to conduct quantitative validation in these patient groups. Future research using 
the FLU-PRO in influenza challenge studies in healthy adults will provide data on the full course of 
influenza, from the pre-influenza asymptomatic state to symptom resolution. The FLU-PRO also is also 
being evaluated for use in influenza-like illness, such as acute respiratory viruses. 
CONCLUSION 
This paper describes the quantitative methods used to develop and test the FLU-PRO for evaluating 
patient-reported symptoms in patients with influenza. Results suggest FLU-PRO scores are reliable, valid, 
and responsive to change in hospitalized and non-hospitalized adults with laboratory-confirmed influenza. 
The instrument is available for use as a standardized method for evaluating symptoms of influenza in 
natural history studies and clinical trials.  
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TABLES 
Table 1. Subject Demographic and Clinical Characteristics by Region: Influenza-Positive Patients 
(N=221) 
Variable 
Day 1 
USA (n=150) Other Countries1 (n=71) 
Age (years)   
Mean (SD) 39.4 (16.1) 43.5 (17.5) 
Median (Range) 36.0 (18–86) 41.0 (18–95) 
>65   
Sex, n (%)   
Female 92 (61.3%) 41 (57.7%) 
Ethnicity, n (%)2   
Hispanic or Latino 16 (10.7%) 67 (94.4%) 
Not Hispanic or Latino 133 (88.7%) 4 (5.6%) 
Race, n (%)   
American Indian or Alaska Native 4 (2.7%) 0  
Asian 5 (3.3%) 0  
Black or African American 74 (49.3%) 0  
Mestizo 0 (0%) 67 (94.4%) 
White 61 (40.7%) 4 (5.6%) 
Other 6 (4.0%) 0  
Employment Status, n (%)   
Employed, full time or part time 81 (54.0%) 33 (46.5%) 
Retired 11 (7.3%) 3 (4.2%) 
Other3 36 (24.0%) 31 (43.7%) 
Missing 22 (14.7%) 4 (5.6%) 
20 
Variable 
Day 1 
USA (n=150) Other Countries1 (n=71) 
Military Status, n (%)   
Never in the military 61 (40.7%) 67 (94.4%) 
Active 40 (26.7%) 0  
Retired 10 (6.7%) 0  
Other4 16 (10.6%) 0  
Missing 23 (15.3%) 4 (5.6%) 
Highest Level of Education, n (%)   
Secondary/high school or less 43 (28.7%) 29 (40.8%) 
Some college 33 (22.0%) 4 (5.6%) 
College degree or more 42 (28.0%) 31 (43.7%) 
Other 32 (21.3%) 7 (9.9%) 
Current Treatments, n (%)   
Oseltamivir (Tamiflu) 50 (33.3%) 13 (18.3%) 
Amantadine (Symmetrel) 0 (0.0%) 2 (2.8%) 
Other 56 (37.3%) 42 (59.2%) 
None 57 (38.0%) 19 (26.8%) 
Co-morbidities5, n (%)   
None 56 (37.3%) 29 (40.8%) 
Asthma 38 (25.3%) 11 (15.5%) 
Chronic Obstructive Pulmonary Disease 
(COPD) 
9 (6.0%) 0 (0.0%) 
Osteoporosis 1 (0.7%) 1 (1.4%) 
Depression 17 (11.3%) 4 (5.6%) 
Hypertension 20 (13.3%) 13 (18.3%) 
Raised cholesterol 12 (8.0%) 10 (14.1%) 
21 
Variable 
Day 1 
USA (n=150) Other Countries1 (n=71) 
Stomach ulcers 3 (2.0%) 3 (4.2%) 
Heart attack/angina 2 (1.3%) 1 (1.4%) 
Diabetes 22 (14.7%) 8 (11.3%) 
Kidney disease 6 (4.0%) 2 (2.8%) 
Lung disease 3 (2.0%) 2 (2.8%) 
Tuberculosis 0 (0.0%) 2 (2.8%) 
Other 39 (26.0%) 17 (23.9%) 
1Other countries include Mexico (n=67), Argentina (n=3), and UK (n=1) 
2One participant had missing ethnicity 
3Other includes homemaker, student, unemployed, and other 
4Other includes reserves and other 
5Not mutually exclusive 
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Table 2. 32-Item FLU-PRO Domain and Total Score Descriptive Statistics (N=221) – Day 1 
Scale Mean (SD) Range, Median (Mode) Floor n (%) Ceiling n (%) 
Nose 1.7 (1.1) 0.0–4.0, 1.5 (1.3) 13 (5.9%) 4 (1.8%) 
Throat 1.4 (1.1) 0.0–4.0, 1.0 (0.0) 41 (18.6%) 5 (2.3%) 
Eyes 1.0 (1.1) 0.0–4.0, 0.7 (0.0) 67 (30.3%) 8 (3.6%) 
Chest/Respiratory 1.9 (0.9) 0.0–4.0, 1.9 (1.7) 3 (1.4%) 2 (0.9%) 
Gastrointestinal 0.7 (0.8) 0.0–3.8, 0.3 (0.0) 77 (34.8%) 0 (0.0%) 
Body/Systemic 1.8 (0.9) 0.0–3.8, 1.8 (2.5) 2 (0.9%) 0 (0.0%) 
Total Score 1.6 (0.7) 0.3–3.7, 1.6 (1.3) 0 (0.0%) 0 (0.0%) 
Note: higher FLU-PRO scores = more severe symptoms. 
Abbreviations: SD=Standard Deviation 
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Table 3. Known-Groups Validity: 32-Item FLU-PRO Scores by Patient Global Rating of Disease Severity, Day 1 
Scale 
Patient Global Rating of Flu Severity 
F Value 
(p-value)1 
Pairwise 
Comparisons2 
 Mean(SD)  
No/Mild Symptoms 
(n=50) 
Moderate Symptoms 
(n=77) 
Severe/Very Severe  
Symptoms 
(n=94) 
Nose 1.29 (0.88) 1.56 (0.95) 2.01 (1.15) 8.9*** 2***,3* 
Throat 0.85 (0.83) 1.24 (1.03) 1.73 (1.24) 11.4*** 2***,3* 
Eyes 0.51 (0.88) 0.82 (0.98) 1.37 (1.19) 12.3*** 2***,3** 
Chest/Respiratory 1.37 (0.69) 1.75 (0.86) 2.20 (0.86) 17.5*** 1*,2***,3** 
Gastrointestinal 0.29 (0.43) 0.48 (0.65) 1.06 (1.00) 19.8*** 2***,3*** 
Body/Systemic 1.03 (0.64) 1.60 (0.78) 2.48 (0.77) 67.5*** 1***,2***,3*** 
Total Score 0.98 (0.47) 1.38 (0.57) 2.01 (0.63) 57.2*** 1***,2***,3*** 
Note: higher FLU-PRO scores = more severe symptoms 
1p values are: *<0.05, **<0.01, ***<0.001; 
2Pairwise comparisons between means will be performed using Scheffe's test adjusting for multiple comparisons: 1=No/Mild symptoms vs Moderate, 2=No/Mild symptoms vs Severe 
and Very Severe, and 3=Moderate symptoms vs Severe and Very Severe. 
Abbreviations: SD=Standard Deviation 
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Table 4. Responsiveness of 32-Item FLU-PRO by Patient Return to Usual Health (N=147)1 or Return to Usual Activities (N=126)2, Day 1 to 
Day 7  
Scale 
Responders3 Non-Responders 
p-value Day 1 
Mean (SD) 
Day 7 
Mean (SD) 
Change Score 
LSMean (SD) 
Day 1 
Mean (SD) 
Day 7 
Mean (SD) 
Change Score 
LSMean (SD) 
Nose        
Usual Health 1.7 (1.1) 0.4 (0.5) 1.3 (0.1) 1.6 (1.1) 0.8 (0.7) 0.8 (0.1) <0.0001 
Usual Activities  1.8 (1.0) 0.6 (0.6) 1.1 (0.1) 1.3 (1.2) 0.7 (1.0) 0.8 (0.1) 0.0375 
Throat        
Usual Health 1.1 (1.0) 0.1 (0.3) 1.2 (0.1) 1.5 (1.2) 0.5 (0.7) 0.9 (0.1) 0.0010 
Usual Activities  1.4 (1.1) 0.3 (0.5) 1.1 (0.1) 1.6 (1.3) 0.6 (0.9) 0.8 (0.1) 0.0244 
Eyes        
Usual Health 1.0 (1.0) 0.1 (0.4) 0.9 (0.1) 1.1 (1.2) 0.4 (0.7) 0.7 (0.1) 0.0452 
Usual Activities  1.0 (1.1) 0.2 (0.6) 0.9 (0.1) 1.3 (1.3) 0.5 (0.8) 0.7 (0.1) 0.1166 
Chest/Respiratory        
Usual Health 1.4 (0.8) 0.5 (0.6) 1.1 (0.1) 2.0 (0.8) 1.2 (0.7) 0.7 (0.1) <0.0001 
Usual Activities  1.8 (0.8) 0.8 (0.7) 1.0 (0.1) 2.0 (0.9) 1.4 (0.8) 0.6 (0.1) 0.0003 
Gastrointestinal        
Usual Health 0.5 (0.8) 0.1 (0.5) 0.5 (0.1) 0.7 (0.8) 0.3 (0.4) 0.4 (0.0) 0.2062 
Usual Activities  0.7 (0.8) 0.2 (0.4) 0.5 (0.0) 0.6 (0.9) 0.4 (0.5) 0.3 (0.1) 0.0169 
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Scale 
Responders3 Non-Responders 
p-value Day 1 
Mean (SD) 
Day 7 
Mean (SD) 
Change Score 
LSMean (SD) 
Day 1 
Mean (SD) 
Day 7 
Mean (SD) 
Change Score 
LSMean (SD) 
Body/Systemic        
Usual Health 1.6 (0.9) 0.2 (0.5) 1.5 (0.1) 1.9 (1.0) 0.6 (0.6) 1.2 (0.1) 0.0004 
Usual Activities  1.9 (0.9) 0.4 (0.5) 1.5 (0.1) 1.9 (1.0) 0.9 (0.8) 1.0 (0.1) <0.0001 
Total Score        
Usual Health 1.3 (0.6) 0.3 (0.4) 1.2 (0.1) 1.6 (0.8) 0.7 (0.5) 0.8 (0.0) <0.0001 
Usual Activities  1.6 (0.7) 0.5 (0.4) 1.1 (0.0) 1.6 (0.8) 0.8 (0.6) 0.7 (0.1) <0.0001 
1Responders: N=51; Non-Responders: N=96 
2Responders: N=87; Non-Responders: N=39 
3Responders are defined as patients responding that they have returned to their usual health or usual activities at day 7. 
Abbreviations: SD=Standard Deviation 
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Figure 1. Final FLU-PRO Conceptual 
Framework
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Figure 2. FLU-PRO Domain and Total Score by Diary Days 1 to 14 
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PHASE I SUPPLEMENTARY TABLES: ALL INFLUENZA POSITIVE PATIENTS 
Table S1. Item Analysis: FLU-PRO Item Descriptive Statistics in Influenza-Positive Patients 
(N=221) – Day 11 
 Mean ± SD Median Mode 
Floor 
n (%) 
Ceiling 
n (%) 
1. Runny or dripping nose 1.8 ± 1.4 2.0 1 44 (19.9%) 35 (15.8%) 
2. Congested or stuffy nose 2.0 ± 1.4 2.0 1 37 (16.7%) 38 (17.2%) 
3. Scratchy or itchy throat 1.7 ± 1.4 1.0 0 60 (27.1%) 35 (15.8%) 
4. Sore or painful throat 1.6 ± 1.4 1.0 0 65 (29.4%) 34 (15.4%) 
5. Swollen throat 0.9 ± 1.2 0.0 0 115 (52.0%) 13 (5.9%) 
6. Difficulty swallowing 0.8 ± 1.1 0.0 0 124 (56.1%) 11 (5.0%) 
7. Teary or watery eyes 1.1 ± 1.3 1.0 0 98 (44.3%) 19 (8.6%) 
8. Sore or painful eyes 0.9 ± 1.3 0.0 0 128 (57.9%) 18 (8.1%) 
9. Eyes sensitive to light 1.0 ± 1.3 0.0 0 126 (57.0%) 19 (8.6%) 
10. Trouble breathing 1.4 ± 1.4 1.0 0 80 (36.2%) 24 (10.9%) 
11. Chest congestion 1.8 ± 1.4 2.0 0 51 (23.1%) 35 (15.8%) 
12. Chest tightness 1.4 ± 1.4 1.0 0 88 (39.8%) 26 (11.8%) 
13. Dry or hacking cough 2.3 ± 1.3 3.0 3 31 (14.0%) 48 (21.7%) 
14. Wet or loose cough 1.5 ± 1.4 1.0 0 69 (31.2%) 23 (10.4%) 
15. Headache 2.1 ± 1.5 2.0 4 48 (21.7%) 60 (27.1%) 
16. Head congestion 1.5 ± 1.4 1.0 0 82 (37.1%) 26 (11.8%) 
17. Sinus pressure 1.4 ± 1.4 1.0 0 89 (40.3%) 23 (10.4%) 
18. Felt dizzy 1.1 ± 1.3 1.0 0 102 (46.2%) 15 (6.8%) 
19. Felt lightheaded 0.9 ± 1.2 0.0 0 117 (52.9%) 13 (5.9%) 
20. Lack of appetite 1.8 ± 1.5 2.0 0 58 (26.2%) 45 (20.4%) 
21. Felt nauseous 1.0 ± 1.3 0.0 0 116 (52.5%) 23 (10.4%) 
22. Stomach ache 0.8 ± 1.2 0.0 0 130 (58.8%) 12 (5.4%) 
23. Sleeping more than 
usual 
1.6 ± 1.5 1.0 0 82 (37.1%) 32 (14.5%) 
24. Difficulty staying asleep 1.7 ± 1.4 2.0 0 69 (31.2%) 34 (15.4%) 
25. Difficulty falling asleep 1.4 ± 1.4 1.0 0 88 (39.8%) 27 (12.2%) 
26. Body aches or pains 2.5 ± 1.5 3.0 4 31 (14.0%) 79 (35.7%) 
27. Weak or tired 2.6 ± 1.3 3.0 4 18 (8.1%) 79 (35.7%) 
28. Chills or shivering 1.9 ± 1.5 2.0 0 63 (28.5%) 46 (20.8%) 
29. Felt cold 2.1 ± 1.5 2.0 3 40 (18.1%) 52 (23.5%) 
30. Felt hot 1.6 ± 1.4 1.0 0 64 (29.0%) 30 (13.6%) 
 Mean ± SD Median Mode 
Floor 
n (%) 
Ceiling 
n (%) 
31. Sweating 1.5 ± 1.4 1.0 0 71 (32.1%) 27 (12.2%) 
32. Felt uncomfortable 2.4 ± 1.4 3.0 4 33 (14.9%) 68 (30.8%) 
33. How many times did you 
vomit 
0.4 ± 0.9 0.0 0 185 (83.7%) 6 (2.7%) 
34. How many times did you 
have diarrhea? 
0.5 ± 1.1 0.0 0 169 (76.5%) 13 (5.9%) 
35. Sneezing 1.6 ± 1.2 1.0 1 48 (21.7%) 11 (5.0%) 
36. Coughing 2.7 ± 1.0 3.0 3 5 (2.3%) 48 (21.7%) 
37. Coughed up mucus or 
phlegm 
1.9 ± 1.3 2.0 2 42 (19.0%) 29 (13.1%) 
1Range for all items: 0.0–4.0 
Abbreviations: SD=Standard Deviation 
 
 
Table S2. Item Analysis: Confirmatory Factor Analysis for FLU-PRO Upper Respiratory, Lower 
Respiratory, and Systemic Domains  
Item Number Standardized Coefficient (SE)1 
Upper Respiratory  
Nose  
1. Runny or dripping nose 0.634 (0.042) 
2. Congested or stuffy nose 0.681 (0.041) 
35. Sneezing 0.453 (0.052) 
Throat  
3. Scratchy or itchy throat 0.760 (0.034) 
4. Sore or painful throat 0.785 (0.032) 
5. Swollen throat 0.720 (0.043) 
6. Difficulty swallowing 0.768 (0.040) 
Eyes  
7. Teary or watery eyes 0.678 (0.043) 
8. Sore or painful eyes 0.812 (0.034) 
9. Eyes sensitive to light 0.803 (0.038) 
Lower Respiratory  
Chest  
10. Trouble breathing 0.743 (0.045) 
11. Chest congestion 0.860 (0.030) 
12. Chest tightness 0.859 (0.032) 
13. Dry or hacking cough 0.655 (0.046) 
14. Wet or loose cough 0.479 (0.060) 
36. Coughing 0.594 (0.053) 
37. Coughed up mucus or phlegm 0.424 (0.065) 
Systemic  
Head  
15. Headache 0.744 (0.034) 
16. Head congestion 0.713 (0.040) 
17. Sinus pressure 0.662 (0.043) 
18. Felt dizzy 0.814 (0.027) 
19. Felt lightheaded 0.776 (0.031) 
Gastrointestinal  
20. Lack of appetite 0.599 (0.047) 
21. Felt nauseous 0.671 (0.044) 
22. Stomach ache 0.647 (0.047) 
Item Number Standardized Coefficient (SE)1 
33. How many times did you vomit? 0.676 (0.056) 
34. How many times did you have diarrhea? 0.321 (0.083) 
Sleep  
23. Sleeping more than usual 0.265 (0.065) 
24. Difficulty staying asleep 0.594 (0.043) 
25. Difficulty falling asleep 0.526 (0.048) 
Body/Systemic  
26. Body aches or pains 0.820 (0.027) 
27. Weak or tired 0.754 (0.034) 
28. Chills or shivering 0.800 (0.029) 
29. Felt cold 0.721 (0.034) 
30. Felt hot 0.579 (0.044) 
31. Sweating  0.537 (0.047) 
32. Felt uncomfortable 0.802 (0.029) 
Comparative Fit Index (CFI) = 0.836, Root Mean Square Error of Approximation (RMSEA) = 0.089, and Weighted Root Mean 
Residual (WRMR) = 1.722. 
1All parameter estimates are p<0.001. 
Abbreviations: SE=Standard error  
 
Table S3. Item Analysis: Exploratory Factor Analysis Standardized Factor Loadings for FLU-PRO 
Items - Seven Factor Solution 
Item Number F1 F2 F3 F4 F5 F6 F7 
1. Runny or dripping nose 0.821 -0.006 -0.024 -0.044 0.087 0.018 0.066 
2. Congested or stuffy nose 0.744 0.081 0.105 0.074 0.065 0.016 -0.048 
35. Sneezing 0.716 0.007 0.127 0.000 -0.083 -0.053 0.049 
3. Scratchy or itchy throat 0.073 0.764 0.027 -0.021 0.047 -0.104 0.084 
4. Sore or painful throat 0.056 0.946 -0.117 -0.091 0.036 0.004 0.039 
5. Swollen throat -0.003 0.787 0.019 0.171 -0.064 0.155 -0.037 
6. Difficulty swallowing -0.106 0.731 0.117 0.271 0.094 0.038 -0.083 
7. Teary or watery eyes 0.424 0.196 0.050 0.451 0.030 -0.044 0.045 
8. Sore or painful eyes 0.315 0.292 0.012 0.758 -0.040 0.015 0.082 
9. Eyes sensitive to light 0.134 0.139 0.018 0.636 0.231 0.022 0.059 
10. Trouble breathing 0.011 0.042 0.564 0.248 0.034 0.087 0.058 
11. Chest congestion -0.004 -0.011 0.801 0.024 0.243 0.016 -0.092 
12. Chest tightness -0.044 -0.041 0.745 0.247 0.180 -0.046 0.010 
13. Dry or hacking cough 0.063 0.046 0.464 -0.008 0.144 -0.138 0.179 
14. Wet or loose cough -0.014 0.036 0.554 -0.309 -0.104 0.391 0.050 
36. Coughing 0.156 0.027 0.595 -0.237 0.070 -0.049 0.080 
37. Coughed up mucus or phlegm 0.072 0.028 0.538 -0.427 -0.092 0.371 0.007 
15. Headache 0.147 0.011 -0.046 0.247 0.640 0.043 -0.026 
16. Head congestion 0.194 0.010 0.137 0.087 0.484 0.209 -0.050 
17. Sinus pressure 0.483 -0.029 0.136 0.005 0.425 0.122 -0.113 
18. Felt dizzy -0.019 -0.003 -0.049 0.220 0.464 0.630 -0.051 
19. Felt lightheaded -0.178 -0.058 0.015 0.162 0.405 0.610 0.119 
20. Lack of appetite 0.024 -0.051 0.064 0.118 0.346 0.180 0.222 
21. Felt nauseous 0.103 0.019 -0.151 -0.072 0.036 0.616 0.585 
22. Stomach ache 0.046 0.144 0.015 0.004 0.035 0.502 0.394 
33. How many times did you vomit? 0.020 0.046 -0.007 -0.171 0.096 0.417 0.643 
34. How many times did you have 
diarrhea? 
0.061 -0.187 0.125 -0.001 0.097 0.155 0.280 
23. Sleeping more than usual 0.063 -0.107 0.066 -0.135 0.467 0.122 -0.250 
24. Difficulty staying asleep -0.170 -0.103 0.069 0.077 0.072 0.052 0.770 
25. Difficulty falling asleep -0.299 0.001 0.118 0.124 -0.123 -0.026 0.902 
26. Body aches or pains 0.065 0.138 -0.114 0.052 0.698 -0.025 0.180 
27. Weak or tired -0.030 0.052 0.021 0.101 0.667 0.105 0.029 
28. Chills or shivering 0.062 0.017 -0.030 -0.032 0.912 -0.293 0.054 
Item Number F1 F2 F3 F4 F5 F6 F7 
29. Felt cold 0.055 -0.029 -0.034 -0.016 0.815 -0.302 0.116 
30. Felt hot -0.306 0.135 0.090 -0.191 0.615 0.003 0.149 
31. Sweating  -0.207 0.104 0.075 -0.203 0.706 -0.023 -0.051 
32. Felt uncomfortable -0.079 0.137 0.019 0.075 0.711 0.015 0.077 
Comparative Fit Index (CFI) = .92, Root Mean Square Error of Approximation (RMSEA) = .058, and Standardized Root Mean 
Square Residual (SRMR) = .046, Test of Close Fit p value = .033 
Color coding represents items within separate body systems. 
PHASE II SUPPLEMENTARY TABLES: ALL INFLUENZA POSITIVE PATIENTS 
Table S4. Two-day Reproducibility of 32-Item FLU-PRO Days 1–7 in Influenza Positive Patients 
FLU-PRO Scores N1 
Mean 
Difference (SD)2 
T 
Statistic 
p-value 
Effect 
Size 
ICC 
Day 1 to Day 2       
Nose 44 0.3 (0.7) 2.78 0.0079 0.25 0.79 
Throat 44 0.3 (1.0) 2.14 0.0382 0.28 0.57 
Eyes 44 0.2 (0.9) 1.27 0.2092 0.17 0.62 
Chest/Respiratory 44 0.1 (0.6) 0.93 0.3591 0.10 0.76 
Gastrointestinal 44 0.2 (0.9) 1.27 0.2092 0.17 0.62 
Body/Systemic 44 0.2 (0.7) 1.53 0.1327 0.17 0.65 
Total Score 44 0.3 (0.6) 3.40 0.0015 0.29 0.83 
Day 2 to Day 3       
Nose 27 0.0 (0.5) 0.11 0.9170 0.01 0.87 
Throat 27 0.1 (0.6) 0.50 0.6209 0.05 0.84 
Eyes 27 -0.0 (0.4) -0.36 0.7223 0.04 0.83 
Chest/Respiratory 27 0.0 (0.4) 0.06 0.9503 0.01 0.85 
Gastrointestinal 27 -0.0 (0.4) -0.36 0.7223 0.04 0.83 
Body/Systemic 27 -0.2 (0.7) -1.48 0.1517 0.47 0.24 
Total Score 27 0.1 (0.5) 0.93 0.3600 0.09 0.86 
Day 3 to Day 4       
Nose 29 -0.1 (0.7) -0.87 0.3891 0.12 0.74 
Throat 29 0.0 (0.5) 0.12 0.9023 0.01 0.91 
Eyes 29 0.1 (0.5) 0.70 0.4892 0.06 0.88 
Chest/Respiratory 29 0.1 (0.5) 0.61 0.5486 0.06 0.86 
Gastrointestinal 29 0.1 (0.5) 0.70 0.4892 0.06 0.88 
Body/Systemic 29 -0.1 (0.6) -0.75 0.4582 0.12 0.64 
Total Score 29 0.0 (0.4) 0.30 0.7637 0.02 0.92 
Day 4 to Day 5       
Nose 18 -0.0 (0.5) -0.37 0.7168 0.04 0.88 
Throat 18 0.2 (0.6) 1.11 0.2840 0.18 0.70 
Eyes 18 0.0 (0.5) 0.15 0.8811 0.02 0.85 
Chest/Respiratory 18 -0.2 (0.5) -1.65 0.1175 0.24 0.77 
Gastrointestinal 18 0.0 (0.5) 0.15 0.8811 0.02 0.85 
Body/Systemic 18 -0.1 (0.3) -0.68 0.5084 0.11 0.76 
Total Score 18 -0.1 (0.4) -1.22 0.2380 0.18 0.79 
Day 5 to Day 6       
Nose 23 -0.0 (0.5) -0.30 0.7633 0.04 0.80 
Throat 23 0.3 (0.8) 1.52 0.1424 0.24 0.60 
FLU-PRO Scores N1 
Mean 
Difference (SD)2 
T 
Statistic 
p-value 
Effect 
Size 
ICC 
Eyes 23 0.1 (0.8) 0.53 0.6041 0.10 0.52 
Chest/Respiratory 23 0.1 (0.4) 1.04 0.3099 0.12 0.84 
Gastrointestinal 23 0.1 (0.8) 0.53 0.6041 0.10 0.52 
Body/Systemic 23 -0.0 (0.3) -0.64 0.5285 0.10 0.76 
Total Score 23 -0.0 (0.3) -0.18 0.8606 0.02 0.90 
Day 6 to Day 7       
Nose 23 -0.1 (0.2) -1.30 0.2077 0.06 0.97 
Throat 23 0.0 (0.2) 0.81 0.4264 0.05 0.96 
Eyes 23 0.1 (0.4) 1.50 0.1479 0.16 0.82 
Chest/Respiratory 23 0.0 (0.4) 0.17 0.8692 0.01 0.92 
Gastrointestinal 23 0.1 (0.4) 1.50 0.1479 0.16 0.82 
Body/Systemic 23 0.1 (0.3) 1.19 0.2451 0.25 0.31 
Total Score 23 0.0 (0.2) 0.60 0.5557 0.05 0.93 
1Number of study participants. 
2Mean difference = average day X FLU-PRO score - average day Y FLU-PRO score (e.g., day 1 score - day 2 score) 
Table S5. Construct Validity: 32-Item FLU-PRO Scale Correlations with Other PRO Measures at 
Day 1 
Day 1 
Domains and Total Score1 
Nose Throat Eyes 
Chest/ 
Respiratory 
Gastrointestinal 
Body/ 
Systemic 
Total 
Score 
Patient Global Rating of Flu 
Severity2 
0.27*** 0.28*** 0.34*** 0.39*** 0.34*** 0.61*** 0.59*** 
Patient Global Rating of 
Physical Health3 
-0.09 -.021* -0.26*** -0.24** -0.06 -0.28*** -0.29*** 
Patient Global Assessment of 
Interference in Daily 
Activities4 
0.11 0.14* 0.28*** 0.29*** 0.22* 0.50*** 0.43*** 
1Spearman correlation coefficients: ***p<0.0001, **p<0.001, *p<0.05 
2Greater values indicate greater disease severity 
3Greater values indicate better patient health 
4Greater values indicate greater interference with daily activities 
PHASE II SUPPLEMENTARY TABLES: STRATIFIED ANALYSES BY HOSPITALIZATION STATUS  
Table S6. Patient Demographic and Clinical Characteristics by Hospitalization Status: Influenza-
Positive Patients (N=221) 
Variable 
Day 1 
Hospitalization1 
(n=53) 
No Hospitalization 
(n=168) 
Age, Years   
Mean (SD) 49.7 (18.6) 37.9 (15.0) 
Median (Range) 50.0 (18–95) 33.0 (18–81) 
>65 9 (17.0%) 10 (6.0%) 
Sex, n (%)   
Female 35 (66.0%) 98 (58.3%) 
Ethnicity, n (%)2   
Hispanic or Latino 29 (54.7%) 54 (32.1%) 
Not Hispanic or Latino 23 (43.4%) 114 (67.9%) 
Race, n (%)   
American Indian or Alaska Native 0  4 (2.4%) 
Asian 0  5 (3.0%) 
Black or African American 17 (32.1%) 57 (33.9%) 
Mestizo 29 (54.7%) 38 (22.6%) 
White 7 (13.2%) 58 (34.5%) 
Other 0  6 (3.6%) 
Employment Status, n (%)   
Employed, full time or part-time 21 (40.0%) 93 (55.3%) 
Retired 5 (9.4%) 9 (5.4%) 
Other3 27 (50.9%) 40 (23.8%) 
Missing 0  26 (15.5%) 
Military Status, n (%)   
Never in the military 53 (100.0%) 75 (44.6%) 
Active 0 40 (23.8%) 
Retired 0 10 (6.0%) 
Other 0  16 (9.5%) 
Missing 0  27 (16.1%) 
Highest Level of Education   
Elementary/primary school 5 (9.4%) 7 (4.2%) 
Secondary/high school or less 24 (45.3%) 48 (28.6%) 
Variable 
Day 1 
Hospitalization1 
(n=53) 
No Hospitalization 
(n=168) 
Some college 8 (15.1%) 29 (17.3%) 
College degree or more 14 (26.4%) 59 (35.1%) 
Other 7 (13.2%) 32 (19.0%) 
Current Treatments, n (%)   
None 13 (24.5%) 63 (37.5%) 
Oseltamivir (Tamiflu) 18 (34.0%) 45 (26.8%) 
Amantadine (Symmetrel) 0  2 (1.2%) 
Other 31 (58.5%) 67 (39.9%) 
Acetaminophen 10 (18.9%) 34 (20.2%) 
Antibiotic 5 (9.4%) 5 (3.0%) 
Antihistamine 0  3 (1.8%) 
Aspirin 3 (5.7%) 1 (0.6%) 
Codeine 1 (1.9%) 0 
Cough suppressant or expectorant 3 (5.7%) 11 (6.5%) 
Decongestant 0  7 (4.2%) 
IV fluids 0  1 (0.6%) 
Inhaled corticosteroid 6 (11.3%) 1 (0.6%) 
Mucolytic 4 (7.5%) 0 (0%) 
NSAID 3 (5.7%) 13 (7.7%) 
OTC: symptom relief 0  3 (1.8%) 
Opioid 1 (1.9%) 0  
Short-acting beta agonist 2 (3.8%) 0  
Co-morbidities5, n (%)   
None 11 (20.8%) 74 (44.0%) 
Asthma 17 (32.1%) 32 (19.0%) 
Chronic Obstructive Pulmonary Disease 
(COPD) 
3 (5.7%) 6 (3.6%) 
Osteoporosis 0  2 (1.2%) 
Depression 5 (9.4%) 16 (9.5%) 
Hypertension 15 (28.3%) 18 (10.7%) 
Raised cholesterol 5 (9.4%) 17 (10.1%) 
Stomach ulcers 1 (1.9%) 5 (3.0%) 
Heart attack/angina 2 (3.8%) 1 (0.6%) 
Diabetes 14 (26.4%) 16 (9.5%) 
Variable 
Day 1 
Hospitalization1 
(n=53) 
No Hospitalization 
(n=168) 
Kidney disease 5 (9.4%) 3 (1.8%) 
Lung disease 3 (5.7%) 2 (1.2%) 
Tuberculosis 0  2 (1.2%) 
Other 16 (30.2%) 40 (23.8%) 
153 patients were hospitalized in the influenza-positive group and 61 patients were hospitalized in the influenza-negative group 
2One person had missing ethnicity 
3Other includes homemaker, student, unemployed, and other 
4Other includes reserves and other 
5Not mutually exclusive 
Table S7a.  32-Item FLU-PRO Domain and Total Score Descriptive Statistics in Non-Hospitalized Influenza-Positive Patients (N=168) - 
Day 1 
Scale Mean (SD) Range, Median (Mode) 
Floor 
n (%) 
Ceiling 
n (%) 
Nose 1.8 ± 1.0 0.0–4.0, 1.8 (1.3) 6 (3.6%) 3 (1.8%) 
Throat 1.5 ± 1.1 0.0–4.0, 1.3 (0.0) 23 (13.7%) 4 (2.4%) 
Eyes 1.0 ± 1.0 0.0–4.0, 0.7 (0.0) 45 (26.8%) 4 (2.4%) 
Chest/Respiratory 1.8 ± 0.9 0.0–3.7, 1.8 (1.7) 3 (1.8%) 0 (0.0%) 
Gastrointestinal 0.6 ± 0.8 0.0–3.5, 0.3 (0.0) 61 (36.3%) 0 (0.0%) 
Body/Systemic 1.9 ± 0.9 0.0–3.8, 2.0 (2.5) 2 (1.2%) 0 (0.0%) 
Total Score 1.6 ± 0.7 0.3–3.4, 1.7 (1.3) 0 (0.0%) 0 (0.0%) 
 
Table S7b.  32-Item FLU-PRO Domain and Total Score Descriptive Statistics in Hospitalized Influenza-Positive Patients (N=53) - Day 1 
Scale Mean (SD) Range, Median (Mode) 
Floor 
n (%) 
Ceiling 
n (%) 
Nose 1.2 ± 1.0 0.0–4.0, 1.0 (1.0) 7 (13.2%) 1 (1.9%) 
Throat 1.1 ± 1.1 0.0–4.0, 0.7 (0.0) 18 (34.0%) 1 (1.9%) 
Eyes 1.0 ± 1.3 0.0–4.0, 0.3 (0.0) 22 (41.5%) 4 (7.5%) 
Chest/Respiratory 1.9 ± 0.9 0.4–4.0, 1.9 (1.9) 0 (0.0%) 2 (3.8%) 
Gastrointestinal 0.8 ± 1.0 0.0–3.8, 0.5 (0.0) 16 (30.2%) 0 (0.0%) 
Body/Systemic 1.6 ± 0.9 0.1–3.6, 1.5 (0.3) 0 (0.0%) 0 (0.0%) 
Total Score 1.4 ± 0.8 0.3–3.7, 1.3 (0.5) 0 (0.0%) 0 (0.0%) 
 
 
Table S8a.  Two-day Reproducibility of 32-Item FLU-PRO Days 1 to Day 7 in Non-Hospitalized 
Influenza-Positive Patients 
FLU-PRO Scores N1 
Day X 
Mean 
(SD) 
Day Y 
Mean 
(SD) 
Mean 
Difference 
(SD)2 
T 
Statistic 
p 
value 
Effect 
Size 
ICC 
Day 1 to Day 2         
    Nose 36 1.8 (1.1) 1.6 (1.1) 0.2 (0.6) 2.29 0.0281 0.20 0.84 
    Throat 36 1.9 (1.2) 1.6 (1.1) 0.3 (1.0) 1.84 0.0740 0.25 0.61 
    Eyes 36 1.0 (1.0) 0.9 (1.1) 0.1 (0.9) 0.71 0.4845 0.11 0.65 
    Chest/Respiratory 36 1.7 (0.8) 1.7 (0.9) -0.0 (0.6) -0.17 0.8664 0.02 0.79 
    Gastrointestinal 36 0.7 (0.9) 0.6 (0.6) 0.2 (0.7) 1.50 0.1424 0.21 0.52 
    Body/Systemic 36 1.9 (1.0) 1.7 (1.1) 0.2 (0.6) 2.49 0.0177 0.23 0.84 
    Total Score 36 1.6 (0.7) 1.5 (0.7) 0.2 (0.4) 2.60 0.0135 0.22 0.85 
Day 2 to Day 3         
    Nose 21 1.2 (0.9) 1.2 (0.9) 0.0 (0.5) 0.11 0.9147 0.01 0.86 
    Throat 21 1.2 (1.2) 1.2 (1.2) 0.1 (0.7) 0.50 0.6236 0.07 0.82 
    Eyes 21 0.6 (0.7) 0.6 (0.7) -0.0 (0.3) -0.21 0.8333 0.02 0.87 
    Chest/Respiratory 21 1.7 (0.8) 1.6 (0.8) 0.1 (0.5) 0.55 0.5915 0.06 0.84 
    Gastrointestinal 21 0.3 (0.5) 0.5 (0.6) -0.1 (0.6) -0.76 0.4554 0.24 0.30 
    Body/Systemic 21 1.3 (1.0) 1.2 (0.8) 0.1 (0.5) 1.11 0.2813 0.12 0.85 
    Total Score 21 1.2 (0.6) 1.1 (0.6) 0.0 (0.3) 0.75 0.4617 0.07 0.89 
Day 3 to Day 4         
    Nose 24 1.4 (0.9) 1.5 (1.0) -0.1 (0.7) -0.76 0.4575 0.11 0.77 
    Throat 24 1.3 (1.1) 1.3 (1.2) 0.0 (0.5) 0.13 0.9013 0.01 0.90 
    Eyes 24 1.0 (1.1) 0.8 (0.9) 0.1 (0.5) 1.31 0.2031 0.13 0.87 
    Chest/Respiratory 24 1.9 (1.0) 1.9 (1.0) 0.0 (0.5) 0.11 0.9151 0.01 0.86 
    Gastrointestinal 24 0.5 (0.6) 0.5 (0.6) -0.1 (0.6) -0.45 0.6591 0.09 0.57 
    Body/Systemic 24 1.5 (1.0) 1.4 (0.9) 0.1 (0.4) 0.88 0.3888 0.07 0.93 
    Total Score 24 1.4 (0.7) 1.4 (0.8) 0.0 (0.3) 0.34 0.7396 0.03 0.93 
Day 4 to Day 5         
    Nose 18 1.5 (1.0) 1.6 (0.9) -0.0 (0.5) -0.37 0.7168 0.04 0.88 
    Throat 18 1.1 (0.9) 0.9 (0.7) 0.2 (0.6) 1.11 0.2840 0.18 0.70 
    Eyes 18 0.8 (0.9) 0.8 (0.9) 0.0 (0.5) 0.15 0.8811 0.02 0.85 
    Chest/Respiratory 18 1.6 (0.8) 1.8 (0.7) -0.2 (0.5) -1.65 0.1175 0.24 0.77 
    Gastrointestinal 18 0.4 (0.5) 0.5 (0.5) -0.1 (0.3) -0.68 0.5084 0.11 0.76 
    Body/Systemic 18 1.1 (0.6) 1.2 (0.6) -0.1 (0.4) -1.22 0.2380 0.18 0.79 
FLU-PRO Scores N1 
Day X 
Mean 
(SD) 
Day Y 
Mean 
(SD) 
Mean 
Difference 
(SD)2 
T 
Statistic 
p 
value 
Effect 
Size 
ICC 
    Total Score 18 1.2 (0.6) 1.2 (0.5) -0.1 (0.3) -1.02 0.3207 0.13 0.84 
Day 5 to Day 6         
    Nose 18 0.9 (0.8) 0.9 (0.8) 0.0 (0.4) 0.00 1.0000 0.00 0.87 
    Throat 18 0.6 (1.0) 0.5 (0.8) 0.1 (0.4) 1.30 0.2097 0.11 0.92 
    Eyes 18 0.3 (0.5) 0.3 (0.5) 0.0 (0.4) 0.22 0.8260 0.04 0.75 
    Chest/Respiratory 18 1.1 (0.7) 1.2 (0.7) -0.0 (0.2) -0.32 0.7557 0.02 0.95 
    Gastrointestinal 18 0.3 (0.5) 0.3 (0.5) -0.0 (0.4) -0.50 0.6260 0.08 0.76 
    Body/Systemic 18 0.6 (0.6) 0.6 (0.6) 0.0 (0.2) 0.45 0.6594 0.03 0.95 
    Total Score 18 0.7 (0.5) 0.7 (0.5) 0.0 (0.1) 0.37 0.7124 0.02 0.97 
Day 6 to Day 7         
    Nose 19 0.9 (1.1) 0.9 (1.2) -0.1 (0.3) -1.10 0.2871 0.06 0.97 
    Throat 19 0.4 (0.6) 0.3 (0.6) 0.0 (0.2) 1.00 0.3306 0.05 0.97 
    Eyes 19 0.4 (0.8) 0.3 (0.5) 0.1 (0.4) 1.57 0.1341 0.18 0.82 
    Chest/Respiratory 19 1.1 (0.9) 1.1 (0.9) 0.0 (0.4) 0.09 0.9332 0.01 0.92 
    Gastrointestinal 19 0.2 (0.3) 0.1 (0.2) 0.1 (0.2) 0.94 0.3597 0.20 0.48 
    Body/Systemic 19 0.5 (0.6) 0.5 (0.7) 0.1 (0.2) 1.36 0.1895 0.10 0.95 
    Total Score 19 0.6 (0.7) 0.6 (0.6) 0.0 (0.2) 1.07 0.2985 0.06 0.97 
1Number of study participants with no change in flu symptom at day Y. 
2Mean difference = average Day X FLU-PRO score - average Day Y FLU-PRO score  (ex. Day 1 score - Day 2 score); p value from 
paired t-test. 
Table S8b.  Two-day Reproducibility of 32-Item FLU-PRO Days 1 to Day 7 in Hospitalized 
Influenza-Positive Patients 
FLU-PRO Scores N1 
Day X 
Mean 
(SD) 
Day Y 
Mean 
(SD) 
Mean 
Difference 
(SD)2 
T 
Statistic 
p 
value 
Effect 
Size 
ICC 
Day 1 to Day 2         
    Nose 8 1.6 (1.4) 1.1 (1.2) 0.6 (1.0) 1.58 0.1580 0.40 0.66 
    Throat 8 1.1 (1.1) 0.7 (0.6) 0.5 (1.3) 1.03 0.3375 0.44 
-
0.04 
    Eyes 8 0.8 (1.1) 0.4 (0.5) 0.5 (0.9) 1.49 0.1806 0.41 0.44 
    Chest/Respiratory 8 1.9 (0.8) 1.4 (0.7) 0.5 (0.5) 3.07 0.0180 0.63 0.68 
    Gastrointestinal 8 0.5 (1.2) 0.5 (1.0) 0.0 (0.3) 0.31 0.7627 0.03 0.97 
    Body/Systemic 8 1.5 (1.0) 0.9 (1.1) 0.6 (0.6) 2.75 0.0286 0.56 0.75 
    Total Score 8 1.4 (0.9) 0.9 (0.8) 0.5 (0.5) 2.67 0.0322 0.51 0.74 
Day 2 to Day 3         
    Nose 6 0.6 (0.6) 0.6 (0.5) 0.0 (0.3) 0.00 1.0000 0.00 0.89 
    Throat 6 0.3 (0.4) 0.3 (0.4) 0.0 (0.0)   0.00 1.00 
    Eyes 6 0.3 (0.4) 0.3 (0.3) -0.1 (0.4) -0.31 0.7711 0.13 0.35 
    Chest/Respiratory 6 0.9 (0.4) 1.1 (0.3) -0.2 (0.3) -1.23 0.2722 0.47 0.49 
    Gastrointestinal 6 0.1 (0.2) 0.6 (0.9) -0.5 (0.8) -1.55 0.1820 2.39 0.20 
    Body/Systemic 6 0.4 (0.2) 0.4 (0.4) -0.0 (0.3) -0.36 0.7327 0.21 0.54 
    Total Score 6 0.5 (0.1) 0.6 (0.2) -0.1 (0.2) -1.67 0.1566 0.99 0.50 
Day 3 to Day 4         
    Nose 5 0.8 (0.6) 0.9 (0.6) -0.2 (0.8) -0.40 0.7102 0.26 
-
0.06 
    Throat 5 0.5 (0.9) 0.5 (1.0) -0.0 (0.2) -0.00 1.0000 0.00 0.98 
    Eyes 5 0.7 (1.3) 1.0 (1.4) -0.3 (0.5) -1.21 0.2943 0.21 0.93 
    Chest/Respiratory 5 1.3 (0.7) 1.1 (0.8) 0.3 (0.4) 1.58 0.1890 0.39 0.83 
    Gastrointestinal 5 0.8 (0.9) 1.0 (0.6) -0.2 (0.5) -0.87 0.4320 0.22 0.80 
    Body/Systemic 5 0.9 (1.0) 1.1 (0.9) -0.2 (0.5) -0.80 0.4669 0.19 0.87 
    Total Score 5 0.9 (0.7) 1.0 (0.7) -0.1 (0.2) -0.68 0.5314 0.10 0.95 
Day 5 to Day 6         
    Nose 5 1.1 (0.8) 1.3 (0.9) -0.2 (0.8) -0.40 0.7102 0.18 0.59 
    Throat 5 0.9 (1.6) 0.1 (0.2) 0.8 (1.6) 1.09 0.3375 0.52 
-
0.10 
    Eyes 5 1.1 (1.7) 0.7 (1.2) 0.3 (1.7) 0.44 0.6808 0.20 0.37 
    Chest/Respiratory 5 1.4 (0.8) 1.0 (0.5) 0.4 (0.6) 1.56 0.1939 0.54 0.52 
FLU-PRO Scores N1 
Day X 
Mean 
(SD) 
Day Y 
Mean 
(SD) 
Mean 
Difference 
(SD)2 
T 
Statistic 
p 
value 
Effect 
Size 
ICC 
    Gastrointestinal 5 0.4 (0.3) 0.5 (0.4) -0.1 (0.2) -0.53 0.6213 0.18 0.82 
    Body/Systemic 5 1.3 (0.8) 1.5 (0.8) -0.1 (0.6) -0.46 0.6710 0.16 0.74 
    Total Score 5 1.1 (0.8) 1.0 (0.5) 0.1 (0.7) 0.40 0.7098 0.17 0.44 
Day 6 to Day 7         
    Nose 4 0.3 (0.4) 0.3 (0.5) -0.1 (0.1) -1.00 0.3910 0.18 0.96 
    Throat 4 0.3 (0.3) 0.3 (0.4) 0.0 (0.3) 0.00 1.0000 0.00 0.73 
    Eyes 4 0.1 (0.2) 0.1 (0.2) 0.0 (0.3) 0.00 1.0000 0.00 
-
0.50 
    Chest/Respiratory 4 0.9 (0.5) 0.9 (0.4) 0.0 (0.2) 0.33 0.7608 0.07 0.92 
    Gastrointestinal 4 0.3 (0.5) 0.1 (0.3) 0.2 (0.6) 0.68 0.5472 0.40 
-
0.09 
    Body/Systemic 4 0.2 (0.1) 0.3 (0.4) -0.1 (0.3) -0.96 0.4058 1.00 0.44 
    Total Score 4 0.4 (0.2) 0.4 (0.2) -0.0 (0.1) -0.45 0.6807 0.11 0.90 
1Number of study participants with no change in flu symptom at day Y. No data available for Day 4 to Day 5. 
2Mean difference = average Day X FLU-PRO score - average Day Y FLU-PRO score (ex. Day 1 score - Day 2 score); p value from 
paired t-test. 
Table S9a.  Construct Validity: 32-Item FLU-PRO Scale Correlations with Other PRO Measures at 
Day 1 in Non-Hospitalized Influenza-Positive Patients 
 Domains and Total Score 
Day Nose Throat Eyes 
Chest/ 
Respiratory 
Gastrointestinal 
Body/ 
Systemic 
Total 
Score 
Day 1        
   Patient Global 
Rating of Flu 
Severity 
0.31*** 0.28** 0.31*** 0.39*** 0.31*** 0.63*** 0.62*** 
   Patient Global 
Rating of Physical 
Health 
-.17* -.25** -.35*** -.23* -.05  -.33*** -.35*** 
   Patient Global 
Assessment of 
Interference in 
Daily Activities 
0.26** 0.21* 0.40*** 0.37*** 0.26** 0.64*** 0.58*** 
1Spearman correlation coefficients: 1p<0.0001, 2p<0.001, 3p<0.05 
 
 
Table S9b.  Construct Validity: 32-Item FLU-PRO Scale Correlations with Other PRO Measures at 
Day in Hospitalized Influenza-Positive Patients 
 Domains and Total Score 
Day Nose Throat Eyes 
Chest/ 
Respiratory 
Gastrointestinal 
Body/ 
Systemic 
Total 
Score 
Day 1        
   Patient Global 
Rating of Flu 
Severity 
0.20  0.31* 0.44** 0.38* 0.42* 0.60*** 0.54*** 
   Patient Global 
Rating of Physical 
Health 
0.12  -.13  -.05  -.28* -.09  -.12  -.13  
   Patient Global 
Assessment of 
Interference in Daily 
Activities 
-.22  0.04  -.08  -.01  0.05  0.13  0.02  
1Spearman correlation coefficients: 1p<0.0001, 2p<0.001, 3p<0.05 
Table S10a.  Known-Groups Validity: 32-Item FLU-PRO Scores by Patient Global Rating of Disease Severity, Day 1 in Non-Hospitalized 
Influenza-Positive Patients 
Scale 
Patient Global Rating of Flu Severity 
F Value 
(p value)1 
Pairwise 
Comparisons2 
 Mean (SD)  
No/Mild Symptoms 
(N=38) 
Moderate Symptoms 
(N=59) 
Severe/Very Severe 
Symptoms 
(N=71) 
Nose 1.40 (0.90) 1.68 (0.92) 2.20 (1.09) 9.3*** 2***,3* 
Throat 1.01 (0.85) 1.25 (1.01) 1.85 (1.24) 9.0*** 2***,3** 
Eyes 0.61 (0.92) 0.80 (0.94) 1.31 (1.07) 7.7*** 2**,3* 
Chest/Respiratory 1.40 (0.65) 1.68 (0.85) 2.21 (0.85) 14.1*** 2***,3** 
Gastrointestinal 0.26 (0.43) 0.47 (0.64) 0.98 (0.94) 13.6*** 2***,3*** 
Body/Systemic 1.10 (0.66) 1.70 (0.77) 2.57 (0.74) 54.5*** 1***,2***,3*** 
Total Score 1.04 (0.45) 1.41 (0.56) 2.06 (0.57) 49.5*** 1**,2***,3*** 
1p values are: *<0.05, **<0.01, ***<0.001. 
2Pairwise comparisons between means will be performed using Scheffe's test adjusting for multiple comparisons: 1=No/Mild symptoms vs Moderate, 2=No/Mild symptoms vs Severe 
and Very Severe, and 3=Moderate symptoms vs Severe and Very Severe. 
  
Table S10b.  Known-Groups Validity: 32-Item FLU-PRO Scores by Patient Global Rating of Disease Severity, Day 1 in Hospitalized 
Influenza-Positive Patients 
Scale 
Patient Global Rating of Flu Severity 
F Value 
(p value)1 
Pairwise 
Comparisons2 
Mean (SD) 
No/Mild Symptoms 
(N=12) 
Moderate Symptoms 
(N=18) 
Severe/Very Severe 
Symptoms  
(N=23) 
Nose 0.92 (0.76) 1.15 (0.97) 1.39 (1.16) 0.9  
Throat 0.36 (0.52) 1.19 (1.13) 1.36 (1.20) 3.7* 2* 
Eyes 0.22 (0.67) 0.89 (1.11) 1.55 (1.52) 4.7* 2* 
Chest/Respiratory 1.27 (0.84) 1.95 (0.87) 2.17 (0.92) 4.1* 2* 
Gastrointestinal 0.38 (0.42) 0.50 (0.70) 1.30 (1.14) 6.2** 2*,3* 
Body/Systemic 0.80 (0.56) 1.28 (0.74) 2.18 (0.80) 15.9*** 2***,3** 
Total Score 0.77 (0.49) 1.27 (0.62) 1.83 (0.77) 10.4*** 2***,3* 
1p values are: *<0.05, **<0.01, ***<0.001. 
2Pairwise comparisons between means will be performed using Scheffe's test adjusting for multiple comparisons: 1=No/Mild symptoms vs Moderate, 2=No/Mild symptoms vs Severe 
and Very Severe, and 3=Moderate symptoms vs Severe and Very Severe. 
Table S11a.  Responsiveness of 32-Item FLU-PRO by Patient Return to Usual Health (N=111) or Return to Usual Activities (N=89), Day 1 
to Day 7 in Non-Hospitalized Influenza-Positive Patients 
Scale 
Responders1 Non-Responders 
p-value2 Day 1 
Mean (SD) 
Day 7 
Mean (SD) 
Change Score 
LSMean (SD) 
Day 1 
Mean (SD) 
Day 7 
Mean (SD) 
Change Score 
LSMean (SD) 
Nose        
Usual Health 1.7 (1.1) 0.4 (0.4) 1.4 (0.1) 1.9 (1.0) 0.9 (0.8) 0.9 (0.1) <.0001 
Usual Activities 1.9 (1.0) 0.6 (0.6) 1.2 (0.1) 1.8 (1.3) 1.0 (1.1) 0.8 (0.1) 0.0114 
Throat        
Usual Health 1.2 (1.0) 0.1 (0.3) 1.4 (0.1) 1.7 (1.2) 0.6 (0.7) 1.0 (0.1) 0.0013 
Usual Activities 1.5 (1.1) 0.3 (0.6) 1.2 (0.1) 2.0 (1.3) 0.8 (1.0) 0.9 (0.1) 0.0466 
Eyes        
Usual Health 1.0 (0.9) 0.1 (0.4) 0.9 (0.1) 1.1 (1.2) 0.3 (0.7) 0.7 (0.1) 0.0955 
Usual Activities 1.1 (1.0) 0.2 (0.6) 0.9 (0.1) 1.3 (1.2) 0.4 (0.7) 0.8 (0.1) 0.4852 
Chest/Respiratory        
Usual Health 1.4 (0.8) 0.5 (0.6) 1.1 (0.1) 2.1 (0.8) 1.3 (0.7) 0.7 (0.1) <.0001 
Usual Activities 1.9 (0.8) 0.9 (0.7) 1.0 (0.1) 2.2 (1.0) 1.6 (1.0) 0.5 (0.1) 0.0006 
Gastrointestinal        
Usual Health 0.4 (0.8) 0.0 (0.2) 0.6 (0.0) 0.7 (0.8) 0.2 (0.4) 0.4 (0.0) 0.0094 
Usual Activities 0.7 (0.8) 0.1 (0.3) 0.6 (0.0) 0.7 (0.9) 0.4 (0.5) 0.3 (0.1) 0.0006 
Body/Systemic        
Usual Health 1.6 (0.9) 0.1 (0.3) 1.7 (0.1) 2.1 (0.9) 0.6 (0.6) 1.3 (0.1) 0.0001 
Usual Activities 2.0 (0.9) 0.3 (0.5) 1.7 (0.1) 2.3 (0.8) 1.0 (0.8) 1.1 (0.1) <.0001 
Total Score        
Usual Health 1.3 (0.6) 0.2 (0.3) 1.3 (0.1) 1.7 (0.7) 0.7 (0.5) 0.9 (0.0) <.0001 
Usual Activities 1.7 (0.7) 0.5 (0.4) 1.2 (0.1) 1.9 (0.6) 1.0 (0.7) 0.8 (0.1) <.0001 
1Responders are defined as patients responding that they have returned to their usual activities at Day 7. 
2From ANCOVA to compare LSMean change scores between responders and non-responders adjusting for Day 1 scores.
Table S11b.  Responsiveness of 32-Item FLU-PRO by Patient Return to Usual Health (N=36) or Return to Usual Activities (N=37), Day 1 to 
Day 7 in Hospitalized Influenza-Positive Patients 
Scale 
Responders1 Non-Responders 
p-value2 Day 1 
Mean (SD) 
Day 7 
Mean (SD) 
Change Score 
LSMean (SD) 
Day 1 
Mean (SD) 
Day 7 
Mean (SD) 
Change Score 
LSMean (SD) 
Nose        
Usual Health 1.4 (0.7) 0.4 (0.7) 0.8 (0.2) 1.0 (0.9) 0.5 (0.6) 0.5 (0.1) 0.2860 
Usual Activities 1.3 (0.8) 0.6 (0.6) 0.5 (0.1) 0.9 (0.9) 0.5 (0.7) 0.6 (0.1) 0.9580 
Throat        
Usual Health 0.8 (1.1) 0.1 (0.3) 0.8 (0.2) 1.1 (1.1) 0.4 (0.8) 0.6 (0.1) 0.3852 
Usual Activities 0.8 (1.0) 0.2 (0.3) 0.7 (0.1) 1.2 (1.1) 0.5 (0.9) 0.6 (0.1) 0.3645 
Eyes        
Usual Health 1.0 (1.3) 0.1 (0.3) 0.9 (0.2) 1.1 (1.4) 0.4 (0.8) 0.6 (0.1) 0.3096 
Usual Activities 0.6 (1.0) 0.1 (0.3) 0.8 (0.1) 1.4 (1.4) 0.6 (0.9) 0.6 (0.1) 0.3756 
Chest/Respiratory        
Usual Health 1.4 (0.6) 0.6 (0.7) 1.1 (0.2) 1.9 (0.9) 1.1 (0.7) 0.8 (0.1) 0.2676 
Usual Activities 1.6 (0.9) 0.6 (0.6) 1.1 (0.1) 1.9 (0.9) 1.2 (0.7) 0.6 (0.1) 0.0410 
Gastrointestinal        
Usual Health 0.6 (0.9) 0.5 (1.1) 0.1 (0.2) 0.6 (0.7) 0.4 (0.5) 0.2 (0.1) 0.4178 
Usual Activities 0.6 (0.7) 0.4 (0.8) 0.2 (0.1) 0.6 (0.8) 0.3 (0.5) 0.2 (0.1) 0.6773 
Body/Systemic        
Usual Health 1.2 (0.8) 0.6 (0.8) 0.7 (0.2) 1.5 (1.1) 0.7 (0.7) 0.7 (0.1) 0.9550 
Usual Activities 1.2 (1.0) 0.5 (0.6) 0.8 (0.1) 1.5 (1.0) 0.8 (0.7) 0.7 (0.1) 0.5442 
Total Score        
Usual Health 1.2 (0.7) 0.5 (0.7) 0.7 (0.1) 1.3 (0.8) 0.7 (0.5) 0.6 (0.1) 0.5134 
Usual Activities 1.1 (0.7) 0.5 (0.5) 0.7 (0.1) 1.4 (0.8) 0.7 (0.6) 0.6 (0.1) 0.3487 
1Responders are defined as patients responding that they have returned to their usual health at Day 7. 
2From ANCOVA to compare LSMean change scores between responders and non-responders adjusting for Day 1 scores. 
 
Figure S1. Preliminary Hypothesized Conceptual Framework: Symptoms of Influenza 
Figure A. Preliminary Hypothesizes Conceptual Framework: 
Symptoms of Influenza 
• Runny or dripping nose
• Congested or stuffy nose
• Sneezing
• Scratchy or itchy throat
• Sore or painful throat
• Swollen throat
• Difficulty swallowing
• Teary or watery eyes
• Sore or painful eyes
• Eyes sensitive to light
• Trouble breathing
• Chest congestion
• Chest tightness
• Dry or hacking cough
• Wet or loose cough
• Coughing
• Coughed up mucus or phlegm
• Headache
• Head congestion
• Sinus pressure
• Felt dizzy
• Felt lightheaded
• Lack of appetite (did not feel like 
eating)
• Felt nauseous (feeling like you 
wanted to throw-up)
• Stomach ache
• Vomit (Frequency)
• Diarrhea (Frequency)
• Sleeping more than usual
• Difficulty staying asleep
• Difficulty falling asleep
• Body aches or pains
• Weak or tired
• Chills or shivering
• Felt cold
• Felt hot
• Sweating
• Felt uncomfortable 
(general discomfort)
Upper Respiratory
Systemic
Lower Respiratory
Flu Symptoms: 
• Presence 
• Severity
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System Overall Concept
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Figure S2. FLU PRO Stage 3: Subject Disposition Chart
 
 
 
Figure S3a. FLU-PRO Domain and Total Score 
by Diary Days 1 to 14: 
Hospitalized, Influenza-Positive 
Patients 
Figure S3b. FLU-PRO Domain and Total Score 
by Diary Days 1 to 14: Non-
Hospitalized, Influenza-Positive 
Patients 
  
 
 
 
 
